Clinical Observation on the Treatment of Macular Edema Secondary to Retinal Vein Occlusion by Liuzi Yangmu Wan Combined with Conbercept Ophthalmic Injection
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).30Keywords:
Liuzi Yangmu Wan, Conbercept Ophthalmic Injection, Retinal Vein Occlusion, Macular Edema, Clinical ObservationAbstract
To observe the effects of Liuzi Yangmu Wan combined with Conbercept Ophthalmic Injection in the treatment of retinal vein occlusion secondary to macular edema on the visual acuity and macular thickness of the patients, and to further clarify its clinical efficacy. Eighty patients diagnosed with retinal vein occlusion at Xi’an Fourth Hospital from July 2021 to July 2023, meeting the inclusion criteria, were randomly divided into two groups using a random number table method: the combination group (40 patients, 40 eyes, treated with Liuzi Yangmu Wan combined with intravitreal injection of Conbercept Ophthalmic Injection), and the control group (40 patients, 40 eyes, treated solely with intravitreal injection of Conbercept Ophthalmic Injection). Both groups followed a “1+PRN” treatment regime based on the patient’s condition. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before treatment and 3, 6 months after treatment, as well as the recurrence rate and number of anti-VEGF injections administered. Before treatment, there was no statistically significant difference between the two groups in BCVA and CMT (P > 0.05). Three months after treatment, compared to before treatment, the BCVA in the combination group improved from 0.81 ± 0.51 to 0.49 ± 0.28 (P < 0.05), and in the control group it improved from 0.79 ± 0.41 to 0.51 ± 0.34 (P < 0.05). The CMT in the combination treatment group decreased from 603.92 ± 249.51μm to 434.90 ± 157.81μm (P < 0.05), and in the control group, it decreased from 595.20 ± 185.93μm to 464.25 ± 122.69μm (P < 0.05), with a significant difference between the two groups (P < 0.05). During the follow-up period, no adverse reactions were observed in any of the patients. The number of injections during the observation period was lower in the combination group (2.15 ± 0.58) compared to the control group (2.63 ± 0.66). Liu Zi Yang Mu Wan is safe and effective in treating retinal vein occlusion, capable of improving patients’ vision, accelerating the resolution of macular edema, and promoting the absorption of hemorrhages. From this, it can be concluded that the combination of Liuzi Yangmu Wan and Conbercept is more effective than the sole use of Conbercept, and it can reduce the number of intravitreal injections needed.
References
Zhao Kanxing, Yang Peizeng. Ophthalmology [M]. 9th edition. Beijing: People’s Medical Publishing House, 2018.
Yong Hongfang, Qi Hui, Wu Yingjie, et al. Research progress on the pathogenesis of macular edema secondary to retinal vein occlusion and its impact on visual function [J]. International Journal of Ophthalmology, 2019, 19(11): 1888-1891.
Rouvas, A., Petrou, P., Ntouraki, A., Douvali, M., Ladas, I. and Vergados, I. (2010) Intravitreal Ranibizumab (Lucentis) for Branch Retinal Vein Occlusion-Induced Macular Edema. Retina, 30, 893-902.
Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009 Jan;116(1):87-93.
Yao, H., Wang, T., Deng, J., et al. (2014) The Development of Blood-Retinal Barrier during the Interaction of Astrocytes with Vascular Wall Cells. Neural Regeneration Research, 9, 1047-1054.
ParodiMB, IaconoP, BandelloF. Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment. Graefes Arch Clin Exp Ophthalmol 2015,253(10):1647-1651
AzadSV, SalmanA, MahajanD, etal. Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion. Middle East Afr J Ophthalmol 2014,21(4):296-30
TanMH, McAllisterIL, GilliesME, etal. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 2014,157(1):237-247
Standards for Diagnosis and Efficacy Evaluation of Traditional Chinese Medicine Diseases and Syndromes (ZY/T001.1-94) [S]. Issued by the National Administration of Traditional Chinese Medicine, 1994: 87-88.
Huang Shuren, Zhang Xiaofeng. Diagnosis and Treatment of Fundus Diseases [M]. 2nd edition. Beijing: People’s Medical Publishing House, 2008.
Li Lingna, Dong Zhijun. Research progress on retinal vein occlusion. International Journal of Ophthalmology, 2020, 20(8): 1371-1374.
Yang Jie, Peng Nanxiang, Chen Jisheng. Comparison of the efficacy of intravitreal injection of different drugs combined with laser treatment for retinal vein occlusion with macular edema. International Journal of Ophthalmology, 2017, 17(10): 1912-1914.
Zhang Minglian, Zhang Yue, Wang Hao, et al. Understanding ischemic eye diseases from the perspective of traditional Chinese medicine’s holistic concept [J]. Chinese Journal of Traditional Chinese Ophthalmology, 2015, 25(06): 408-411.
Fu Renyu. A Review of Yao Han [M]. Taiyuan: Shanxi Science and Technology Press, 2013: 56.
Han Zhihua, Wu Yini, Wang Fang, et al. Mechanism of Zhixue Quyu Mingmu Tablets in non-ischemic retinal vein occlusion [J]. Chinese Journal of Traditional Chinese Ophthalmology, 2019, 29(3): 197-201.
Wang Kentang. Standards of Diagnosis and Treatment (Volume 7) [M]. Edited by Ni Hexian. Beijing: People’s Medical Publishing House, 2014: 100.
Pang Wu, Zhang Minglian, Pang Zhaoshan, et al. Discussion on Pang Zanxiang’s “Theory of Multiple Depressions in Eye Diseases” and his medication experience [J]. Chinese Journal of Traditional Chinese Ophthalmology, 2015, 25(06): 431-433.
Zhang Weiqiong, Li Jun, Jie Chuanhong, et al. Application of the theory “Liver Opens to the Eyes” in internal eye diseases [J]. Chinese Journal of Traditional Chinese Ophthalmology, 2021, 31(05): 347-350.
Chang X, Chen X, Guo Y, Gong P, Pei S, Wang D, Wang P, Wang M, Chen F. Advances in Chemical Composition, Extraction Techniques, Analytical Methods, and Biological Activity of Astragali Radix. Molecules. 2022 Feb 4;27(3):1058.
Zhang Q, Gao WY, Man SL. [Chemical composition and pharmacological activities of astragali radix]. Zhongguo Zhong Yao Za Zhi. 2012 Nov;37(21):3203-7. Chinese. PMID: 23397713.
Yang Yang, Wan Feng, Hou Xiaomeng, et al. Study on the components promoting the proliferation activity of neural stem cells in Rehmannia glutinosa [J]. Central South Pharmacy, 2024, 22(05): 1201-1206.
Lou Tianyu, Li Ruiji, Liu Jinhui, et al. Bioassay method for Danshen injection based on in vitro antiplatelet aggregation activity [J]. Chinese Pharmacological Bulletin, 2020, 36(06): 875-879.
Ran X, Ma L, Peng C, Zhang H, Qin LP. Ligusticum chuanxiong Hort: a review of chemistry and pharmacology. Pharm Biol. 2011 Nov;49(11):1180-9.
Zeng P, Li J, Chen Y, Zhang L. The structures and biological functions of polysaccharides from traditional Chinese herbs. Prog Mol Biol Transl Sci. 2019,163:423-444.
Pharmacopoeia Commission of the People’s Republic of China. Pharmacopoeia of the People’s Republic of China: 2020 Edition, Part 1 [M]. Beijing: China Medical Science Press, 2020: 349-350.
LiX, XuG, WangY, etal. Safety and efficacy of conbercept in neovascular age-related macular degeneration: resultsfrom a12-month randomized phase 2 study: AURORA study. Ophthalmology 2014,121(9): 1740-1747
Yu Pan. Comparison of the Effects of Vitreous Cavity Injection of Conbercept and Ranibizumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion [J]. China Modern Drug Application, 2019, 13(15): 125-126.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jinyifu Zhu, Yurong Yang, Xiaoqin Lei
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
